Welcome to ConjuGon, Inc
Our mission is to develop fundamentally new ways to prevent and treat bacterial infections. Bacterial infections cause millions of people to be hospitalized each year in the U.S. and result in nearly 100,000 deaths annually. Many of these infections were once easily and successfully treated with antibiotics however bacterial strains that were resistant to many of these antibiotics developed over time. These antibiotic-resistant bacteria are better able to survive than many of their antibiotic-sensitive cousins, such that in many hospitals and communities most of the bacteria are now overwhelmingly resistant to antibiotics. New antibiotic therapies are desperately needed.
Following the early discovery of several antibiotics between 1935 and 1962, no new classes of antibiotics were introduced for nearly forty years and many of these antibiotics are no longer effective. ConjuGon, Inc. is actively advancing valuable and novel technologies that use harmless bacteria as drugs. Currently, the company is advancing the technology of Bacterial Interference for the prevention of Catheter-Associated Urinary Tract Infections (commonly referred to as CAUTI) and Conjugation-Based Killing Technology for the prevention and treatment of wound infections. Conjugation-based killing is effective against antibiotic-resistant bacteria, including bacteria that are resistant to all available antibiotics, and has been carefully designed to prevent the development of resistance.
ConjuGon's first product for the prevention of CAUTI is currently in human clinical trials.